Extent and sources of geographic variation in medicare end-stage renal disease expenditures

被引:24
|
作者
Hirth, RA
Tedeschi, PJ
Wheeler, JRC
机构
[1] Univ Michigan, Sch Publ Hlth, Dept Hlth Management & Policy, Ann Arbor, MI 48109 USA
[2] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA
[3] Univ Michigan, Kidnet Epidemiol & Cost Ctr, Ann Arbor, MI 48109 USA
关键词
chronic kidney failure; Medicare; costs and cost analysis; physicians' practice patterns;
D O I
10.1053/ajkd.2001.27702
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Geographic variations in practices and expenditures have been widely documented, leading to concerns that care in some regions is clinically suboptimal and/or economically inefficient. Our objectives are to determine the extent and sources of geographic variation in Medicare expenditures per patient with end-stage renal disease (ESRD) per year. The study population Included all patients with ESRD with Medicare as primary payer during 1997 (n = 284,670). Medicare expenditures were summarized at the hospital referral region (HRR) level. Using regression analysis, we estimated the relationship between expenditures and demographics, case mix, dialysis provider characteristics, distribution of patients across renal replacement therapy modalities, standardized hospitalization ratios, and healthcare wages. Spending per patient-year varied threefold across HRRs, ranging from $17,791 to $59,025 (mean, $38,966 +/- $6,774 [SD]). The regression equation explained 80% of this variation. Although several demographic and case-mix indicators that have been related to spending at the individual level were statistically significant predictors of spending at the HRR level, they did not show enough geographic variation to explain a large fraction of spending variation. Rather, patient distributions across renal replacement modalities, hospitalization patterns, and healthcare wages were the most powerful predictors of spending. Compared with Medicare generally, both the mean and SD of ESRD expenditures were approximately seven times larger. The substantial geographic variability in expenditures for patients with ESRD indicates the potential for improving efficiency and quality of care. Interventions designed to increase transplantation rates, ensure access to peritoneal dialysis, and reduce hospitalization appear most promising. (C) 2001 by the National Kidney Foundation, Inc.
引用
收藏
页码:824 / 831
页数:8
相关论文
共 50 条
  • [1] Medicare expenditures in periods before and after end-stage renal disease (ESRD).
    St Peter, WL
    Khan, SS
    Ebben, JP
    Li, S
    Xue, JL
    Pereira, BJG
    Collins, AJ
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2002, 13 : 621A - 621A
  • [2] GEOGRAPHIC-VARIATION IN THE INCIDENCE OF TREATED END-STAGE RENAL-DISEASE
    FOXMAN, B
    MOULTON, LH
    WOLFE, RA
    GUIRE, KE
    PORT, FK
    HAWTHORNE, VM
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 1991, 2 (06): : 1144 - 1152
  • [3] Medicare part D and end-stage renal disease
    不详
    [J]. DIALYSIS & TRANSPLANTATION, 2007, 36 (09) : 476 - 476
  • [4] MEDICARE PROGRAM FOR END-STAGE RENAL-DISEASE
    WEINSTEIN, AB
    [J]. ARCHIVES OF INTERNAL MEDICINE, 1978, 138 (12) : 1776 - 1776
  • [5] Impact of initial dialysis modality and modality switches on Medicare expenditures of end-stage renal disease patients
    Shih, YCT
    Guo, A
    Just, PM
    Mujais, S
    [J]. KIDNEY INTERNATIONAL, 2005, 68 (01) : 319 - 329
  • [6] Regional variation in end-stage renal disease
    Usami, T
    Sato, R
    Yoshida, A
    Kimura, G
    [J]. CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2002, 11 (03): : 343 - 346
  • [7] How end-stage renal disease (ESRD)-medicare developed
    Schreiner, GE
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2000, 35 (04) : S37 - S44
  • [8] TRANSPLANTATION AND THE MEDICARE END-STAGE RENAL-DISEASE PROGRAM
    BROGAN, D
    TUTTLE, EP
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1988, 319 (01): : 55 - 55
  • [9] HISTORY OF END-STAGE RENAL DISEASE AND MEDICARE BENEFITS FOR DIALYSIS
    Whitney, Lori L.
    [J]. JOURNAL OF LEGAL MEDICINE, 2017, 37
  • [10] How end-stage renal disease (ESRD)-Medicare developed
    Schreiner, GE
    [J]. SEMINARS IN NEPHROLOGY, 1997, 17 (03) : 152 - 159